The physics behind the approach is as unusual as it is promising. Cold atmospheric plasma is a partially ionized gas generated at room temperature, typically from a carrier gas such as argon. Unlike the hot plasmas found in stars or industrial cutters, medical plasmas remain cool enough to touch living tissue, yet they deliver a potent cocktail of reactive oxygen and nitrogen species (RONS), charged particles, electromagnetic fields, and ultraviolet radiation. Cancer cells, which already live on the edge of oxidative stress because of their altered redox balance and elevated baseline levels of reactive oxygen species, are thought to be particularly vulnerable when an extra oxidative push tips them over their antioxidant threshold. Healthy cells, with more robust buffering capacity, may tolerate the same dose — a therapeutic window that plasma researchers have been chasing for more than a decade.

What makes the Tübingen study distinctive is its indirect delivery strategy. Rather than directing the plasma jet at cells themselves, the researchers used a clinical-grade electrosurgical setup — the VIO 3 generator with an APC 3 argon plasma module from Erbe Elektromedizin — to irradiate cell culture medium for two minutes from a fixed distance of seven millimeters. This treatment loads the liquid with long-lived reactive species, chiefly hydrogen peroxide, nitrite, and nitrate, which persist after the plasma is switched off. The resulting plasma treated medium can be stored, dosed in standardized dilutions, and, crucially, applied to parts of the body that a plasma jet could never reach directly — a decisive advantage for a cancer that seeds microscopic deposits across the abdominal lining.

To test the concept, the team worked with three established ovarian cancer cell lines chosen to represent different therapy response profiles: OVCAR-3, derived from a cisplatin-resistant high-grade adenocarcinoma; OVCAR-29, from an ovarian adenocarcinoma; and HEY, from a papillary cystadenocarcinoma with reported taxane resistance. After 18 hours of exposure to serial dilutions of PTM, cell viability measured by a resazurin assay dropped in a dose-dependent manner across all three lines. The potency varied considerably: HEY and OVCAR-3 cells were highly susceptible, with half-maximal inhibitory concentrations at dilutions of 1:3.6 and 1:4 respectively, while OVCAR-29 cells required a far more concentrated 1:1.1 dilution to reach the same effect.

Perhaps the most eye-catching finding concerned the cisplatin-resistant line. OVCAR-3 cells, which shrug off one of the standard chemotherapy drugs used against ovarian cancer, proved among the most sensitive to the plasma-derived reactive species. The authors suggest that resistance to conventional chemotherapy does not necessarily confer resistance to PTM, implying that plasma treatment exploits vulnerabilities distinct from those targeted by platinum and taxane drugs. If this holds up in further studies, plasma-based approaches could offer a route to attacking tumors that have already outmaneuvered the pharmacological arsenal — one of the most pressing unmet needs in gynecological oncology.

Dissecting the mechanism of cell death revealed a multi-pronged assault. In HEY and OVCAR-29 cells, PTM triggered phosphorylation of the histone variant H2AX, a well-established molecular flag for DNA double-strand breaks, alongside significant activation of caspases 3 and 7, the executioner enzymes of apoptosis. Cell cycle analysis by flow cytometry showed shifts consistent with checkpoint activation in response to oxidative DNA damage, with cells accumulating in the G1 phase and a corresponding decline in the G2 fraction. OVCAR-3 cells told a more nuanced story: caspase activity showed only a rising trend and H2AX phosphorylation was not detectable under the applied conditions, hinting that DNA-damage-independent routes — or simply insufficient dosing within the observation window — may contribute to cytotoxicity in this line.

The metabolic arm of the study employed one of the most elegant tools in modern cell biology: fluorescence lifetime imaging microscopy, or FLIM. Because the respiratory chain coenzymes NADH and FAD are naturally autofluorescent, the duration of their fluorescence after excitation reveals whether they are free in the cytosol or bound to mitochondrial proteins, and how the electron transport chain is coping. After just one hour of PTM exposure, the proportion of free NADH fell significantly in HEY and OVCAR-29 cells, while the fluorescence lifetimes of both free and protein-bound NADH and FAD shifted in patterns consistent with an imbalance between electron carrier formation and oxidation — a signature of impaired oxidative phosphorylation.

The mitochondrial damage extended to structure and electrical function. Staining with tetramethylrhodamine (TMRM), a dye that accumulates in mitochondria in proportion to membrane potential, showed significantly prolonged fluorescence lifetimes in HEY and OVCAR-29 cells after treatment, indicating depolarization of the mitochondrial membrane. Meanwhile, the physiological filamentous, thread-like mitochondrial networks of untreated cells collapsed into punctate, partly vesicular fragments — a morphological hallmark of mitochondrial injury frequently seen on the road to apoptosis. Together, the FLIM data and the TMRM measurements sketch a coherent picture: plasma-derived reactive species strike the bioenergetic core of the cancer cell, crippling its power supply and dismantling the organelles that decide its fate.

Crucially, the team did not stop at immortalized cell lines. They isolated primary tumor cells from the ascites — the fluid accumulating in the abdomen — of eight consenting ovarian cancer patients, using repeated partial trypsinization and immunofluorescence staining for the ovarian carcinoma marker PAX8 and the mesothelial marker calretinin to confirm that roughly 90 percent of the recovered cells were indeed malignant. When these patient-derived high-grade serous carcinoma cultures were exposed to PTM, viability fell by about 40 percent at a 1:9 dilution, with an IC50 at 1:5. Yet the response pattern differed markedly from the cell lines: caspase activation and H2AX phosphorylation were minimal, and instead the cells shifted from the G1 phase into S phase, with the S-phase fraction rising from 5 to 12 percent. The mitochondria of these primary cells also resisted depolarization and fragmentation.

This attenuated response, the authors argue, reflects the adaptive resilience of tumor cells conditioned to survive in the hostile, oxidative environment of the peritoneal cavity — cells equipped with robust DNA repair capacity, metabolic plasticity, and possibly stem-like survival programs. It is a sobering reminder that laboratory cell lines can overstate therapeutic efficacy, and it underscores why the inclusion of patient-derived material is becoming the gold standard in preclinical cancer research. The study has clear limitations: all experiments were conducted in vitro, no comparison with standard chemotherapeutics was performed, non-malignant ovarian cells were not tested, and mechanistic validation by Western blotting or ROS-scavenging interventions remains to be done. Even so, the clinical logic is compelling. Because complete cytoreductive surgery is the single strongest prognostic factor in ovarian cancer — yet occult microscopic deposits persist even after macroscopically perfect resections — a storable, doseable liquid that kills residual tumor cells could one day complement surgery in both complete and incomplete cytoreduction settings. The next steps, the researchers say, are validation in animal models and combination studies with standard chemotherapy regimens, as the field of plasma medicine edges closer to the operating theater.

Subject of Research: Antitumor effects of cold atmospheric plasma treated medium in human ovarian cancer cells

Article Title: Cold atmospheric plasma treated medium (PTM) induce antitumor effects in human ovarian cancer cells

Article References: Keßler, F., Oelkrug, F., Oberlechner, E., Andress, J., Brucker, S. Y., Koch, A., Berrio, D. A. C., Schenke-Layland, K., & Weiss, M. (2026). Cold atmospheric plasma treated medium (PTM) induce antitumor effects in human ovarian cancer cells. Cancer Cell International, 26(1), Article 330. https://doi.org/10.1186/s12935-026-04461-6

Image Credits: AI Generated

DOI: 10.1186/s12935-026-04461-6

Keywords: ovarian cancer, cold atmospheric plasma, plasma treated medium, reactive oxygen and nitrogen species, DNA damage, mitochondrial dysfunction, apoptosis, fluorescence lifetime imaging microscopy, ascites-derived tumor cells, plasma medicine, cancer metabolism, cell cycle

The research team, led by Xiaofeng Dai, Yixuan Yang, Xibo Xue, and Yi Lv of the First Affiliated Hospital of Xi’an Jiaotong University, developed a material they call FAE@CHG. The system combines two engineered components: functional nanoparticles that capture short-lived radicals generated by cold atmospheric plasma, and a tyramine-conjugated hyaluronic acid hydrogel that holds the loaded nanoparticles in place and releases their cargo gradually over time. According to the authors, this hybrid platform preserved highly reactive oxygen and nitrogen species for up to three weeks, an extraordinary extension of lifetimes that naturally range on the order of microseconds.

To understand why this matters, it helps to consider what cold atmospheric plasma actually is. Unlike the hot plasmas found in stars or fusion reactors, cold atmospheric plasma operates near room temperature at atmospheric pressure, typically generated by applying high voltage to a gas such as helium or air. The result is a complex mixture of electrons, ions, ultraviolet photons, and chemically active molecules, including reactive oxygen species such as hydroxyl radicals and hydrogen peroxide, and reactive nitrogen species such as nitric oxide. The short-lived radicals among these are widely considered central to plasma’s potent anticancer effects, but they decay almost instantly upon contact with surfaces or liquids, which has severely limited how the technology can be delivered.

One workaround that researchers have explored is plasma-activated medium, in which a liquid is exposed to plasma and then applied to cells or tissue. The problem, as the study’s authors note, is that such liquids end up dominated by longer-lived species like hydrogen peroxide and nitrite, while the short-lived radicals that make direct plasma treatment so effective are lost almost entirely. Plasma-activated medium therefore captures only a fraction of plasma’s therapeutic chemistry. The new hydrogel strategy was designed specifically to close that gap, giving clinicians a way to store and transport the most reactive components of plasma rather than settling for their diluted, longer-lived remnants.

The capturing element of the system, designated FAE, consists of nanoparticles with a magnetic iron oxide core, a gold shell, and a functional surface layer, produced by pre-treating the particles with cold atmospheric plasma. These nanoparticles act as radical sponges, binding the short-lived reactive species generated during plasma exposure. The second element, HAT, is a hydrogel formed from hyaluronic acid conjugated with tyramine, a modification that allows the gel network to be stabilized and tuned for sustained release. Together, the nanoparticle-hydrogel composite holds the captured radicals in a form that remains chemically active long after the plasma source has been switched off.

Three weeks of preservation is not merely a storage convenience. It transforms the logistics of plasma medicine. A treatment that once required a plasma generator at the bedside could, in principle, be prepared in advance, stored, and applied topically like a conventional pharmaceutical gel. The authors emphasize that this is the first successful integration of plasma-derived short-lived reactive species into a gel-based platform, a milestone that could expand plasma therapy’s administration routes well beyond the operating theater and the direct-contact applicator.

The team tested their material against cutaneous squamous cell carcinoma, a common skin cancer, chosen both for its clinical relevance and for its accessibility to topical treatment. In cell studies, FAE@CHG produced a potent and selective anticancer response, attacking tumor cells while sparing non-malignant counterparts. What distinguishes the mechanism is its breadth: rather than triggering a single death pathway, the trapped radicals activated multiple regulated cell death programs simultaneously. The authors report that this coordinated assault was primarily orchestrated by disulfidptosis, a recently identified form of regulated cell death driven by the accumulation of disulfide molecules that disrupt the actin cytoskeleton and cause cells to collapse and die.

Disulfidptosis is an unusually attractive mechanism for cancer therapy because it depends on cellular metabolic vulnerabilities that many tumors cannot easily evade. Unlike apoptosis, the most familiar cell death pathway, disulfidptosis can be induced under conditions of high glucose and impaired disulfide metabolism, and cancer cells with certain metabolic profiles are particularly susceptible. By making disulfidptosis the primary orchestrator of cell death while simultaneously engaging additional pathways, the hydrogel appears to present tumor cells with a multi-front challenge that is harder to resist than any single mechanism. Resistance to cancer therapies often emerges when cells adapt to one death pathway; concurrent activation of several may reduce the escape routes available.

Animal models provided the crucial confirmation that the laboratory results translated into living systems. Tumors treated with FAE@CHG showed enhanced efficacy compared with control treatments, and the material caused no apparent systemic toxicity whether applied topically or as part of an integrated treatment regimen. That safety profile is essential for a platform built on reactive chemistry, since the same radical species that kill cancer cells can damage healthy tissue if released indiscriminately. The hydrogel’s ability to contain and gradually release these species appears to concentrate their effects where they are needed while protecting surrounding tissue.

The work was funded by the National Natural Science Foundation of China, and the authors declare no competing interests. Its implications extend beyond skin cancer. Because the platform is modular, a hydrogel loaded with plasma-activated nanoparticles could potentially be adapted to other tumor types, combined with existing therapies, or engineered for different release profiles. It also addresses a persistent criticism of plasma medicine, namely that its clinical translation has been hampered by the difficulty of delivering its active chemistry in a controlled, reproducible way. By converting a transient physical phenomenon into a storable, stable material, the researchers have effectively turned cold atmospheric plasma from a device-dependent procedure into something closer to a drug. If subsequent studies replicate these findings and establish clinical safety, the microsecond radicals that once evaporated into thin air could become a lasting weapon in oncology’s arsenal.

Subject of Research: A nanoparticle-hydrogel platform that preserves short-lived cold atmospheric plasma radicals to induce disulfidptosis in cutaneous squamous cell carcinoma

Article Title: A strategy trapping transient radicals from cold atmospheric plasma triggers disulfidptosis of cancer cells

Article References: Dai, X., Yang, Y., Xue, X., & Lv, Y. (2026). A strategy trapping transient radicals from cold atmospheric plasma triggers disulfidptosis of cancer cells. Advanced Composites and Hybrid Materials. https://doi.org/10.1007/s42114-026-02051-8

Image Credits: AI Generated

DOI: 10.1007/s42114-026-02051-8

Keywords: cold atmospheric plasma, disulfidptosis, hydrogel, reactive oxygen species, nanoparticles, cutaneous squamous cell carcinoma, plasma medicine, regulated cell death, cancer therapy, radical preservation, hyaluronic acid, drug delivery